资料显示，嘉和美康(北京)科技股份有限公司位于北京市海淀区东北旺西路8号院28号楼1层101，成立 日期2006年3月3日，上市日期2021年12月14日，公司主营业务涉及从事医疗信息化软件研发与产业化。 主营业务收入构成为：自制软件销售47.70%，软件开发及技术支持服务39.84%，外采软硬件销售 12.18%，其他(补充)0.27%。 从基金十大重仓股角度 责任编辑：小浪快报 数据显示，国新国证基金旗下1只基金重仓嘉和美康。国新国证新利A（001797）二季度持有股数9000 股，占基金净值比例为1.39%，位居第五大重仓股。根据测算，今日浮亏损失约1.76万元。 国新国证新利A（001797）成立日期2015年9月2日，最新规模1902.33万。今年以来收益10.7%，同类排 名5589/8194；近一年收益16.08%，同类排名6057/7963；成立以来亏损14.1%。 8月27日，嘉和美康跌5.13%，截至发稿，报36.25元/股，成交2.99亿元，换手率5.77%，总市值49.87亿 元。 国新国证新利A（001797）基金经理为张洪磊。 截至发稿，张洪磊累计任职时间3年356天，现任基金资产 ...

Company Overview - Madi Technology closed at 15.44 yuan, up 2.93%, with a latest price-to-book ratio of 5.75 and a total market capitalization of 4.729 billion yuan [1] - As of the first quarter of 2025, there is one institutional holder of Madi Technology, holding a total of 49.2201 million shares valued at 0.637 billion yuan [1] Business Operations - Suzhou Madi Technology Co., Ltd. specializes in providing Clinical Information System (CIS) application software and overall solutions for clinical information management [1] - The company's main products include self-developed software, comprehensive solutions, purchased software and hardware, operational and technical services, medical service income, and photovoltaic battery cells [1] Financial Performance - For the first quarter of 2025, Madi Technology reported operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1] - The net profit for the same period was 23.5959 million yuan, showing a year-on-year increase of 138.55% [1] - The sales gross margin stood at 66.10% [1] Industry Comparison - Madi Technology's price-to-earnings (P/E) ratio (TTM) is -17.79, while the industry average is 113.36 [2] - The industry median P/E ratio is 20.17, indicating that Madi Technology's valuation is significantly lower than the industry average [2] - The total market capitalization of Madi Technology is 4.729 billion yuan, compared to the industry average of 11.359 billion yuan [2]